Clinical trials: Ischemic Stroke or High-risk TIA (ABCD² ≥ 4)
Ischemic Stroke or High-risk TIA (ABCD² ≥ 4)
INtensive liPid-lowering Therapy for Acute High-risk IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2)
The research team is conducting a randomized, double-blind, placebo-controlled, multicenter clinical study aimed at evaluating the impact of adding Tolecilimab (a PCSK9 inhibitor) to standard lipid-lowering therapy (statins ±…
- Trial name
- NCT07341958
- Testing
- Tafolecimab
- Where
- China
- Volunteers
- 242 people
- Sponsor
- Beijing Tiantan Hospital
Ischemic Stroke or High-risk TIA (ABCD² ≥ 4)
Safety and Efficacy of CG-BM1 in Ischemic Stroke
1. To evaluate the safety and tolerability of CG-BM1 for the treatment of patients with Ischemic Stroke. 2. To observe the preliminary effectiveness of CG-BM1 in treating Ischemic Stroke patients.
- Trial name
- NCT07896941
- Testing
- single infusion, 1.0 × 10^6 cells/kg, single infusion, 2.0 × 10^6 cells/kg, single infusion, 3.0 × 10^6 cells/kg
- Where
- China
- Volunteers
- 87 people
- Sponsor
- GuangZhou Cellgenes Biotechnology Co., Ltd.